Rubella epidemiology in Lesotho after vaccine introduction: a five-year review, 2018-2022.
Congenital Rubella Syndrome
Lesotho
Rubella
Vaccination
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
18 Oct 2024
18 Oct 2024
Historique:
received:
14
03
2024
accepted:
13
09
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
The rubella virus is a major contributor to birth defects globally and is preventable by vaccination. In 2020, the world was supposed to be free of both rubella and Congenital Rubella Syndrome (CRS) however this goal has yet to be realized with only 93 out of 194 WHO member states confirmed rubella-free in 2020. A retrospective measles and rubella case-based surveillance data record review was conducted from 2018 to 2022 to document rubella epidemiology after the introduction of rubella vaccination in Lesotho and progress toward elimination. All samples submitted for surveillance purposes and tested for rubella were considered but only filtered according to inclusion and exclusion criteria. Descriptive statistics were used to analyse the data. Of the 1041 samples that were tested for rubella between 2018 and 2022, 10 (1%) were confirmed measles positive and were excluded from further analysis. The median age of the respondents was 6.0 (IQR 4.0-8.0.) years. About 643 (62.4%) of respondents were in the age category of 5 - <13 years. Rubella prevalence was 1% (95% CI; 0.5 -1.8%). The non-measles, non-rubella rash illness rate of 2 per 100 000 population was obtained at the national level each year of the study period but by only 2 of the country's 10 districts in 2021. The study showed low rubella prevalence. Rubella infection was predominant in those aged 5 - < 13 years. Failure to meet surveillance targets at certain time points during the study period may have led to an underestimation of rubella cases. There is a need to improve the quality of measles and rubella surveillance in Lesotho. Supplementary immunization activities would also be useful in closing immunity gaps, limiting outbreaks, and advancing rubella and CRS elimination in Lesotho.
Sections du résumé
BACKGROUND
BACKGROUND
The rubella virus is a major contributor to birth defects globally and is preventable by vaccination. In 2020, the world was supposed to be free of both rubella and Congenital Rubella Syndrome (CRS) however this goal has yet to be realized with only 93 out of 194 WHO member states confirmed rubella-free in 2020.
METHODS
METHODS
A retrospective measles and rubella case-based surveillance data record review was conducted from 2018 to 2022 to document rubella epidemiology after the introduction of rubella vaccination in Lesotho and progress toward elimination. All samples submitted for surveillance purposes and tested for rubella were considered but only filtered according to inclusion and exclusion criteria. Descriptive statistics were used to analyse the data.
RESULTS
RESULTS
Of the 1041 samples that were tested for rubella between 2018 and 2022, 10 (1%) were confirmed measles positive and were excluded from further analysis. The median age of the respondents was 6.0 (IQR 4.0-8.0.) years. About 643 (62.4%) of respondents were in the age category of 5 - <13 years. Rubella prevalence was 1% (95% CI; 0.5 -1.8%). The non-measles, non-rubella rash illness rate of 2 per 100 000 population was obtained at the national level each year of the study period but by only 2 of the country's 10 districts in 2021.
CONCLUSIONS
CONCLUSIONS
The study showed low rubella prevalence. Rubella infection was predominant in those aged 5 - < 13 years. Failure to meet surveillance targets at certain time points during the study period may have led to an underestimation of rubella cases. There is a need to improve the quality of measles and rubella surveillance in Lesotho. Supplementary immunization activities would also be useful in closing immunity gaps, limiting outbreaks, and advancing rubella and CRS elimination in Lesotho.
Identifiants
pubmed: 39425042
doi: 10.1186/s12889-024-20081-z
pii: 10.1186/s12889-024-20081-z
doi:
Substances chimiques
Rubella Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2874Informations de copyright
© 2024. The Author(s).
Références
WHO Vaccine-Preventable Diseases Surveillance Standards Rubella Vaccine-. Preventable Diseases Surveillance Standards [Internet]. https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_20_Rubella_R2.pdf?ua=1
Zimmerman LA, Knapp JK, Antoni S, Grant GB, Reef SE. Progress toward Rubella and congenital Rubella Syndrome Control and Elimination — Worldwide, 2012–2020. MMWR. 2022;71(6):196–201.
pubmed: 35143468
pmcid: 8830626
WHO Measles and Rubella Strategic Framework 2021–2030. https://s3.amazonaws.com/wp-agility2/measles/wp-content/uploads/2020/11/measles_rubella_initiative_final_print.pdf
WHO Immunization Data portal [Internet]. immunizationdata.who.int. https://immunizationdata.who.int . Accessed 15 June 2024.
Patel MK, Antoni S, Danovaro-Holliday MC, Desai S, Gacic-Dobo M, Nedelec Y et al. The epidemiology of rubella, 2007–18: an ecological analysis of surveillance data. The Lancet Glob Health [Internet]. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30320-X/fulltext
WHO Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. [Internet]. 2020 Jul 3 [cited 2022 Oct 1];95(27):306–24. https://apps.who.int/iris/handle/10665/332952
Nwako AB, Makhupane T. The epidemiology of Rubella in Lesotho before the introduction of a Rubella Containing Vaccine: a review of Measles Case-based Surveillance, 2012–2016. IJTDH. 2021;22–31.
Makhupane T, Nwako B. The Burden of Disease from Congenital Rubella Syndrome in Lesotho. [cited 2021 Oct 20]; https://www.longdom.org/open-access/the-burden-of-disease-from-congenital-rubella-syndrome-in-lesotho.pdf
Lopez AL, Raguindin PF, del Rosario JJ, Najarro R, Du E, Aldaba J, et al. The burden of congenital rubella syndrome in the Philippines: results from a retrospective assessment. WPSAR. 2017;8(2):17–24.
doi: 10.5365/wpsar.2017.8.1.006
pubmed: 29184700
pmcid: 5695426
Hong H, Malfeld S, Smit S, Makhathini L, Fortuin M, Motsamai T et al. A retrospective 5-year review of rubella in South Africa prior to the introduction of a rubella-containing vaccine. Mossong J, editor. PLOS One. [Internet]. 2022;17(5):e0265870. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071131/
Forrest JM, Turnbull FM, Sholler GF, Hawker RE, Martin FJ, Burgess MA et al. Gregg’s congenital rubella patients 60 years later. MJA. [Internet]. 2002 Dec [cited 2019 Dec 17];177(11):664–7. https://www.mja.com.au/journal/2002/177/11/greggs-congenital-rubella-patients-60-years-later
Cooper LZ. The history and medical consequences of rubella. Reviews of infectious diseases [Internet]. 1985;7 Suppl 1: S2-10. https://www.ncbi.nlm.nih.gov/pubmed/3890105
Ministry of Health of Lesotho. Post campaign evaluation coverage survey for mass measles rubella vaccination and soil transmitted helminths medicine administration activities. 2017. Not published.
Plotkin SA. Rubella Eradication: not yet accomplished, but entirely feasible. J Infect Dis. 2021;224(Supplement4):S360–6.
doi: 10.1093/infdis/jiaa530
pubmed: 34590132
pmcid: 8482023
Kirman JR, Quinn KM, Seder RA. Immunological memory. Immunol. Cell Biol. [Internet]. 2019;97(7):615–6. https://pubmed.ncbi.nlm.nih.gov/31283852/
Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA, Rubella. Lancet. [Internet]. 2015;385(9984):2297–307. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514442/
African Regional guidelines for measles and rubella surveillance. - African regional guidelines for measles and rubella surveillance who Regional Office for Africa [Internet]. https://www.afro.who.int/sites/default/files/2017-06/who-african-regional-measles-and-rubella-surveillance-guidelines_updated-draft-version-april-2015_1.pdf
Nsubuga F, Ampaire I, Kasasa S, Luzze H, Kisakye A. Positive predictive value and effectiveness of measles case-based surveillance in Uganda, 2012–2015. Selvey LA, editor. PLOS One. 2017;12(9): e0184549.
Luce R, Masresha B, Katsande R, Fall A, Shibeshi M. The impact of recent rubella vaccine introduction in 5 countries in the African Region. J Immunol Sci. 2018;2(SI1):108–12.
doi: 10.29245/2578-3009/2018/si.1116
Dongdem AZ, Alhassan E, Opare D, Boateng G, Bosu G, Amponsa-Achiano K et al. An 11-year trend of rubella incidence cases reported in the measles case-based surveillance system, Ghana. Pan Afr Med j. 2021;39.
Dalton M, Sanderson B, Robinson LJ, Homer CSE, Pomat W, Danchin M, et al. Impact of COVID-19 on routine childhood immunisations in low- and middle-income countries: a scoping review. PLOS Glob Public Health. 2023;3(8):e0002268. https://doi.org/10.1371/journal.pgph.0002268 .
doi: 10.1371/journal.pgph.0002268
pubmed: 37611014
pmcid: 10446229
Shet A, Carr K, Danovaro-Holliday MC, Sodha SV, Prosperi C, Wunderlich J, Wonodi C, Reynolds HW, Mirza I, Gacic-Dobo M, O’Brien KL, Lindstrand A. Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories. Lancet Global Health. 2022;10(2):e186–94. https://doi.org/10.1016/s2214-109x(21)00512-x .
doi: 10.1016/s2214-109x(21)00512-x
pubmed: 34951973
Lumley SF, Richens N, Lees E, Cregan J, Kalimeris E, Oakley S, Morgan M, Segal S, Dawson M, Walker AS, Eyre DW, Crook DW, Beer S, Novak A, Stoesser NE, Matthews PC. Changes in paediatric respiratory infections at a UK teaching hospital 2016–2021; impact of the SARS-CoV-2 pandemic. J Infect. 2021. https://doi.org/10.1016/j.jinf.2021.10.022 .
doi: 10.1016/j.jinf.2021.10.022
pubmed: 34757137
pmcid: 8591975
Fricke LM, Glöckner S, Dreier M, Lange B. Impact of non-pharmaceutical interventions targeted at COVID-19 pandemic on influenza burden – a systematic review. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.11.039 .
doi: 10.1016/j.jinf.2020.11.039
pubmed: 33278399
pmcid: 9183207
Rau C, Lu ̈decke D, Dumolard LB, Grevendonk J, Wiernik BM, Kobbe R, et al. Data quality of reported child immunization coverage in 194 countries between 2000 and 2019. PLOS Glob Public Health. 2022;2(2):e0000140. https://doi.org/10.1371/journal.pgph.0000140 .
doi: 10.1371/journal.pgph.0000140
pubmed: 36962284
pmcid: 10022119
Scobie HM, Edelstein M, Nicol E, Morice A, Rahimi N, MacDonald NE, Danovaro-Holliday C, M. and, Jawad J. Improving the quality and use of immunization and surveillance data: Summary report of the Working Group of the Strategic Advisory Group of experts on immunization. Vaccine. 2020;38(46):7183–97. https://doi.org/10.1016/j.vaccine.2020.09.017 .
doi: 10.1016/j.vaccine.2020.09.017
pubmed: 32950304
pmcid: 7573705
Hübschen JM, Bork SM, Brown KE, Mankertz A, Santibanez S, Ben Mamou M, et al. Challenges of measles and rubella laboratory diagnostic in the era of elimination. Clin Microbiol Infect. 2017;23(8):511–5.
doi: 10.1016/j.cmi.2017.04.009
pubmed: 28412379
Yousif M, Hong H, Malfeld S, Smit S, Makhathini L, Motsamai T et al. Measles incidence in South Africa: a six-year review, 2015–2020. BMC Public Health. 2022;22(1).
Davidkin I, Jokinen S, Broman M, Leinikki P, P., and, Peltola H. 2008. ‘Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: A 20-year follow-up’, Journal of Infectious Diseases, 197(7), pp. 950–956. https://doi.org/10.1086/528993
Crooke SN, Riggenbach MM, Ovsyannikova IG, Warner ND, Chen M-H, Hao L, Icenogle JP, Poland GA, Kennedy RB. Durability of humoral immune responses to rubella following MMR vaccination. Vaccine. 2020;38(51):8185–93. https://doi.org/10.1016/j.vaccine.2020.10.076 .
doi: 10.1016/j.vaccine.2020.10.076
pubmed: 33190948
pmcid: 7716653